China Regenerative Medicine International Limited

Total Valuation

China Regenerative Medicine International Limited carries a market capitalization of 85.19M, placing it among publicly traded companies globally. Its enterprise value stands at 203.84M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

China Regenerative Medicine International Limited currently has 304.25M shares outstanding.

Valuation Ratios

China Regenerative Medicine International Limited trades at a trailing price-to-earnings ratio of 294.46. The price-to-sales ratio is 2.26, and the price-to-book ratio stands at -0.06.

Enterprise Valuation

On an enterprise value basis, China Regenerative Medicine International Limited trades at an EV/EBITDA multiple of 95.69 and an EV/FCF ratio of 208.22. The EV/Sales ratio of 2.93 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 95.69 provides insight into valuation relative to core operating earnings.

Financial Position

China Regenerative Medicine International Limited maintains a current ratio of 1.14, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 425.60, indicating elevated leverage, while an interest coverage ratio of -26.63 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Stock Price Statistics

China Regenerative Medicine International Limited's stock has declined approximately -42.26804% over the past 52 weeks. The 50-day moving average sits at 0.35, while the 200-day moving average is 0.43.

Income Statement

Over the trailing twelve months, China Regenerative Medicine International Limited generated 69.49M in revenue and converted that into -107.70M in net income, yielding earnings per share of -0.38. EBITDA reached -26.07M, while operating income came in at -26.07M.

Balance Sheet

China Regenerative Medicine International Limited holds 3.33M in cash and equivalents against 50.19M in total debt, resulting in a net debt position of 31.87M. Total book value stands at -2.82B, with working capital of 20.79M providing operational flexibility.

Margins

China Regenerative Medicine International Limited operates with a gross margin of 27.95, reflecting its pricing power and cost economics. The operating margin of -37.52 and net profit margin of -154.99 provide insight into operational efficiency.

Stock Splits

China Regenerative Medicine International Limited's most recent stock split took place on September 6, 2023 with a 10:1 split ratio.

Scores

China Regenerative Medicine International Limited posts an Altman Z-Score of -21.11, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.